natgillin/translations-raw huggingface dataset:
No dose adjustment of Harvoni or tacrolimus is required.
Odmerka zdravila Harvoni ali takrolimusa ni treba prilagajati.
As Harvoni contains ledipasvir and sofosbuvir, any interactions that have been identified with these active substances individually may occur with Harvoni.
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Zdravilo Harvonivsebuje ledipasvir in sofosbuvir, zato se pri uporabi zdravila Harvonilahko pojavijo katere koli interakcije, ki so jih opazili pri uporabi teh posameznih zdravilnih učinkovin.
Co-administration of Harvoni with tipranavir (ritonavir boosted) is expected to decrease the concentration of ledipasvir, leading to reduced therapeutic effect of Harvoni.
Harvoni s tipranavirjem (okrepljenim z ritonavirjem) zmanjšalo koncentracijo ledipasvirja,
HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS Efavirenz/ emtricitabine/ tenofovir disoproxil fumarate (600 mg/ 200 mg/ 300 mg/ once daily)/ ledipasvir (90 mg once daily)
PROTIVIRUSNA ZDRAVILA PROTI HIV: ZAVIRALCI REVERZNE TRANSKRIPTAZE Efavirenz/ emtricitabin/ dizoproksiltenofovirat fumarat (600 mg/ 200 mg/ 300 mg/ enkrat na dan)/ ledipasvir (90 mg enkrat na dan)c/ sofosbuvir (400 mg enkrat na dan)c, d
NS
Z
Titanium dioxide
Zaviralci protonske črpalke
Emtricitabine ↔ Cmax 1.02 (0.96, 1.08) ↔ AUC 1.04 (1.00, 1.08) ↔ Cmin 1.03 (0.97, 1.10)
Ledipasvir ↔ Cmax 1,11 (0,99; 1,24) ↔ AUC 1,12 (1,00; 1,25) ↔ Cmin 1,17 (1,04; 1,31)
Patient population*
Dispozicija bolnika
However, it is not recommended that ribavirin be increased to the originally assigned dose (1,000 mg to 1,200 mg daily).
Prilagajanje odmerka ribavirina pri bolnikih, ki jemljejo 1.000-1.200 mg na dan
Genotype 1a a
Ravni HCV RNA ob izhodišču a
Ledipasvir
↑ Lopinavir
No Yes a. One patient was excluded from the LDV/SOF 12-week treatment arm and one patient was excluded from the LDV/SOF+RBV 24-week treatment arm as both patients were infected with genotype 4 CHC.
Ne Da a. En bolnik iz skupine 12-tedenskega zdravljenja z LDV/SOF in en bolnik iz skupine 24-tedenskega zdravljenja z
↔ Cmin 1.07 (0.89, 1.28)
↔ Cmax 0,97 (0,83; 1,14)
Yes d
Ne d f
Emtricitabine ↔ Cmax 1.08 (0.97, 1.21)
↔ Cmin 0,91 (0,83; 0,99) Emtricitabin ↔ Cmax 1,08 (0,97; 1,21)
↔ Cmin 1.12 (1.05, 1.20) Ledipasvir ↔ Cmax 1.10 (1.01, 1.19)
↔ Cmin 1,08 (0,98; 1,20) Ritonavir ↔ Cmax 1,17 (1,01; 1,35)
Esomeprazolee
Okskarbazepin
• palpitations
• zasoplost
The safety of these vaccines should continue to be carefully monitored.
Varnost teh zdravil je treba še naprej skrbno spremljati.
On 09 July 2015 the European Commission therefore triggered a procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data, and requested the EMA to assess these concerns.
Zato je 9. julija 2015 Evropska komisija na podlagi farmakovigilančnih podatkov sprožila postopek v skladu s členom 20 Uredbe (ES) št. 726/2004 in zahtevala od agencije EMA, da oceni omenjene pomisleke.
The vast majority of POTS reports came from a centre in Denmark (Brinth et al, 2015)1.
Velika večina poročil o sindromu POTS izhaja iz centra na Danskem (Brinth idr., 2015)1.
POTS is a systemic syndrome which has been known for a long time under different names and is still poorly understood.
Sindrom POTS je sistemski sindrom, ki je pod različnimi imeni znan že dolgo časa in je še vedno slabo razumljen.
• The Pharmacovigilance Risk Assessment Committee (PRAC) considered the procedure under Article 20 of Regulation (EC) No 726/2004 for HPV vaccines.
• Odbor za oceno tveganja na področju farmakovigilance (PRAC) je upošteval postopek v skladu s členom 20 Uredbe (ES) št. 726/2004 o cepivih proti virusu HPV;
In this respect, the CHMP commented that these comparisons should take into account likely increasing awareness of these syndromes to ensure appropriate interpretation of emerging data.
V zvezi s tem je odbor CHMP pripomnil, da bo treba pri teh primerjavah upoštevati verjetno naraščajočo prepoznavnost teh sindromov, s čimer se zagotovi ustrezna interpretacija dobljenih podatkov.
The benefits of HPV vaccines continue to outweigh their risks.
Koristi cepiv proti virusu HPV so še vedno večje od tveganj.
Human papillomavirus (HPV) vaccines have been authorised in the European Union since 2006 for the prevention of cervical and various other cancers caused by HPV infection.
Cepiva proti humanemu papilomavirusu (HPV) so v Evropski uniji od leta 2006 odobrena za preprečevanje raka materničnega vratu in drugih vrst raka, ki jih povzroča okužba s HPV.
The onset of symptoms of CRPS is difficult to define because the syndrome is usually only diagnosed from the point when normal recovery from the initiating trauma should have occurred, and is usually only recognised sometime later among those with continuing pain afterwards.
Pojav simptomov sindroma CRPS je težko opredeliti, saj se sindrom po navadi diagnosticira šele tedaj, ko bi moralo po začetni travmi priti do okrevanja, in se običajno prepozna šele pozneje pri tistih, ki še vedno trpijo zaradi stalne bolečine.
2 Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK.
Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK (Bivalentno cepivo proti humanemu papilomavirusu in tveganje za sindrome utrujenosti pri deklicah v Združenem kraljestvu).
This is in accordance with the Scientific advisory group conclusions that most of the reviewed reports of POTS could better correspond to the definition of CFS or at least include some features of CFS.
To je v skladu z zaključki znanstvene svetovalne skupine, po katerih večina pregledanih poročil o sindromu POTS bolj ustreza opredelitvi sindroma CFS oziroma vsaj vključuje nekatere značilnosti sindroma CFS.
As many of the reports considered in the review have features of CFS and some patients had diagnoses of both POTS and CFS, these results were considered relevant for the current evaluation.
Ker številna poročila, zajeta v pregledu, vključujejo značilnosti sindroma CFS, nekateri bolniki pa imajo diagnozo sindromov POTS in CFS, so bili ti rezultati pomembni za trenutno ocenjevanje.
Use of these vaccines is expected to prevent many cases of cervical cancer and various other cancers and conditions caused by HPV.
Pričakuje se, da se z uporabo teh cepiv preprečijo številni primeri raka materničnega vratu in drugih vrst raka ter bolezni, ki jih povzroča virus HPV.
The PRAC noted that some symptoms of these syndromes may overlap with chronic fatigue syndrome (CFS, also known as myalgic encephalomyelitis or ME).
Odpor PRAC je poudaril, da se nekateri simptomi teh sindromov lahko prekrivajo s sindromom kronične utrujenosti (CFS, znanim tudi kot mialgični encefalomielitis oziroma ME).
• The PRAC took note of the fact that CRPS and POTS occur in the general unvaccinated population and have been described in the medical literature before HPV vaccines were introduced.
• odbor PRAC se je seznanil z dejstvom, da se sindroma CRPS in POTS pojavljata tudi v splošnem, necepljenem prebivalstvu in da sta bila opisana v medicinski literaturi že pred uvedbo cepiv proti virusu HPV;
POTS patients typically show persistent tachycardia for more than 10 minutes upon standing, as well as an increase in heart rate to above 120 bpm or by ≥ 30bpm, and in children and juveniles below 19 years of age by ≥ 40bpm, without arterial hypotension.
Pri bolnikih s sindromom POTS se praviloma pojavita trajna tahikardija, ki traja več kot 10 minut po vstajanju, in povečanje srčnega utripa na več kot 120/min ali za ≥ 30/min ter pri otrocih in mladostnikih, mlajših od 19 let, za ≥ 40/min, brez arterijske hipotenzije.
This included the responses submitted by the marketing authorisation holders, published literature, Eudravigilance data, and the outcome of the Scientific advisory group (SAG) on vaccines as well as data submitted by member states and information submitted by the public.
Podatki so vključevali tudi odgovore imetnikov dovoljenja za promet z zdravilom, objavljeno literaturo, podatke iz sistema Eudravigilance in zaključke znanstvene svetovalne skupine (SAG) o cepivih ter podatke, ki so jih predložile države članice, in informacije, ki jih je posredovala javnost;
A study by Donegan and colleagues (2013)2, using self-controlled case series design (and therefore avoiding the issue of differential diagnostic practice in vaccinated and unvaccinated), evaluated diagnoses of CFS, as well as referrals from general practice for as yet undiagnosed symptoms of chronic fatigue and exhaustion, as well as diagnoses for fibromyalgia, post viral syndrome and neurasthenia.
V študiji, ki je je opravil Donegan s sodelavci (2013)2, v kateri je uporabil zasnovo s samonadzorovano serijo primerov (in se tako izognil vprašanju diferencialne diagnostične prakse pri cepljenih in necepljenih), so ocenjevali diagnoze sindroma CFS in napotitve osebnih zdravnikov zaradi še nediagnosticiranih simptomov kronične utrujenosti in izčrpanosti ter diagnoz fibromialgije, postvirusnega sindroma n nevrastenije.
The review found no evidence that the overall rates of these syndromes in vaccinated girls were different from expected rates in these age groups, even taking into account possible underreporting.
S pregledom niso dokazali, da se pojavnost sindromov pri cepljenih deklicah razlikuje od pričakovane pojavnosti v tej starostni skupini, tudi z upoštevanjem morebitnega pomanjkljivega poročanja.
The SAG also concluded that most of the reports of CRPS under review did not appear to fulfil the established diagnostic criteria for CRPS.
Skupina SAG je zaključila tudi, da večina pregledanih poročil o sindromu CRPS ni izpolnjevala uveljavljenih diagnostičnih kriterijev za sindrom CRPS.
The PRAC requested data and analyses from the MAHs regarding CRPS and POTS from clinical trials and post-marketing safety data, and took into account literature review, data from Eudravigilance, reports submitted by member states, including Denmark, as well as information from Japan and information submitted voluntarily by the public.
Odbor PRAC je od imetnikov dovoljenja za promet z zdravili zahteval podatke in analize o sindromih CRPS in POTS iz kliničnih preskušanj in podatke o varnosti iz obdobja trženja ter je upošteval pregled literature, podatke iz sistema Eudravigilance, poročila, ki so jih predložile države članice, vključno z Dansko, ter informacije z Japonske in podatke, ki jih je prostovoljno posredovala javnost.
This centre has recently published more information on these reports, suggesting that some of these individuals were likely to have had chronic fatigue syndrome (CFS).
Iz tega centra so nedavno objavili več informacij o teh poročilih, ki kažejo, da imajo nekatere osebe verjetno sindrom kronične utrujenosti (ang.
Overall, in these analyses the rates of these syndromes in vaccinated girls were consistent with expected rates in these age groups.
Skupno je bila pojavnost sindromov v teh analizah pri cepljenih deklicah skladna s pričakovano pojavnostjo v tej starostni skupini;
CRPS typically follows an episode of trauma including fracture of the wrist or carpal tunnel syndrome surgery, or immobilisation of the limb.
Sindrom CRPS praviloma sledi epizodi travme, vključno z zlomom zapestja ali s kirurškim posegom pri sindromu karpalnega kanala, ali imobilizaciji okončine.
Analyses of observed versus expected number of spontaneous reports were undertaken, covering a wide range of scenarios regarding underreporting (from 1 - 100 % reporting) and including reports that did not fully meet the diagnostic criteria for the syndrome.
Opravili so analize dejanskega števila spontanih poročil v primerjavi s pričakovanim številom in pri tem zajeli širši spekter scenarijev pomanjkljivega poročanja (v razponu med 1- in 100-odstotnim poročanjem) ter vključili poročila, ki niso popolnoma ustrezala diagnostičnim kriterijem za sindrom.
In the review of clinical trial data a total of 60,594 subjects were included for Gardasil/Silgard and Gardasil 9 and 42,047 subjects for Cervarix.
Pri pregledu podatkov iz kliničnih preskušanj je bilo vključenih 60 594 preiskovank, cepljenih s cepivom Gardasil/Silgard in Gardasil 9, ter 42 047 preiskovank, cepljenih s cepivom Cervarix.
• The PRAC also noted that many of the reviewed reports of POTS had features in common with chronic fatigue syndrome (CFS).
• odbor PRAC je tudi ugotovil, da so imela številna pregledana poročila o sindromu POTS skupne značilnosti s sindromom kronične utrujenosti (CFS).
It was agreed that employing broad search strategies to identify possible cases of CRPS and POTS and ongoing comparison of reporting rates against available information on the known epidemiology of CRPS and POTS is important.
Dogovorjeno je bilo, da sta uporaba razširjenih iskalnih strategij za prepoznavanje morebitnih primerov sindromov CRPS in POTS ter stalno primerjanje pogostnosti navedb z razpoložljivimi informacijami o znani epidemiologiji sindromov CRPS in POTS pomembni.
• The PRAC considered that the observed versus expected analyses took into account a wide range of scenarios regarding underreporting and included reports that did not fully meet the diagnostic criteria for the syndromes.
• odbor PRAC je presodil, da so analize primerjave med dejansko in pričakovano pojavnostjo upoštevale širok spekter scenarijev glede pomanjkljivega poročanja in da so vključevale poročila, ki niso v celoti izpolnjevala diagnostičnih kriterijev za sindroma.
Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papillomavirus; Vaccine, 2015; 33(22):2602-5.
Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papillomavirus (Ortostatska intoleranca in sindrom posturalne tahikardije kot domnevni neželeni učinek cepljenja proti humanemu papilomavirusu).
The advice of the Scientific advisory group (SAG) on vaccines was sought; the expertise of this group was supplemented with additional European experts on these syndromes and on neurology, cardiology and pharmacoepidemiology.
Izkušnje te skupine so dopolnili z izkušnjami drugih evropskih strokovnjakov za ta sindroma ter strokovnjakov za nevrologijo, kardiologijo in farmakoepidemiologijo.
CRPS is defined as continuing pain that is disproportionate to the inciting event and may be associated with dysautonomic signs and symptoms and is usually confined to a single limb.
Sindrom CRPS je opredeljen kot stalna bolečina, nesorazmerna z dogodkom, ki jo je izzval, in je lahko povezan z znaki in simptomi okvare avtonomnega živčevja ter je običajno omejen na eno okončino.
A diagnosis of POTS cannot solely rely on these criteria; other symptoms (e.g. syncope, fatigue, headaches, lightheadedness, diaphoresis, tremor, palpitations, exercise intolerance, near syncope upon standing upright) vary across patients and are otherwise non-specific.
Drugi simptomi (npr. sinkopa, utrujenost, glavoboli, vrtoglavica, diaforeza, tremor, palpitacije, zmanjšana telesna zmogljivost, delna sinkopa ob vstajanju) se med bolniki razlikujejo in so nespecifični.
Taking into account the totality of the available information the PRAC concluded that the evidence does not support that HPV vaccines (Cervarix, Gardasil, Gardasil 9, Silgard) cause CRPS or POTS.
Z upoštevanjem vseh razpoložljivih informacij je odbor PRAC zaključil, da ni dokazov, da cepiva proti virusu HPV (Cervarix, Gardasil, Gardasil 9, Silgard) povzročajo sindrom CRPS ali POTS.
Routine surveillance of suspected adverse reaction reports has raised questions on the potential association between the use of the vaccines and two syndromes in particular, which are known as Complex regional pain syndrome (CRPS) and Postural orthostatic tachycardia syndrome (POTS).
Redno spremljanje poročil o domnevnih neželenih učinkih je sprožilo vprašanja o možni povezavi med uporabo cepiv in zlasti dvema sindromoma, znanima kot kompleksni regionalni bolečinski sindrom (CRPS) in sindrom posturalne ortostatske tahikardije (POTS).
Overall, comparisons of observed versus expected number of spontaneous reports, with the same scenarios as described above for CRPS, do not suggest an increased occurrence of POTS in relation to the HPV vaccines.
Na splošno primerjave med dejanskim in pričakovanim številom spontanih poročil, z enakimi scenariji, kot so opisani zgoraj za sindrom CRPS, ne kažejo na povečano pojavnost sindroma POTS v povezavi s cepivi proti virusu HPV.
• The PRAC considered the totality of the data submitted with regard to a potential association between HPV vaccination and the occurrence of Complex regional pain syndrome (CRPS) and Postural orthostatic tachycardia syndrome (POTS).
• odbor PRAC je preučil vse predložene podatke, ki se nanašajo na morebitno povezavo med cepljenjem proti virusu HPV ter pojavom kompleksnega regionalnega bolečinskega sindroma (CRPS) in sindroma posturalne ortostatske tahikardije (POTS).
This should include follow-up of CRPS or POTS reports to determine relevant clinical characteristics, to identify possible cases of POTS and CRPS based on broad search strategies including outcome details and to compare reporting rates against available information on the known epidemiology of POTS and CRPS.
To spremljanje mora vključevati nadaljnje spremljanje poročil o sindromih CRPS in POTS za določanje pomembnih kliničnih značilnosti, ugotavljanje morebitnih primerov sindromov POTS in CRPS na podlagi strategij razširjenega iskanja, vključno s podatki o izidu, in za primerjavo pogostnosti navedb z razpoložljivimi informacijami o znani epidemiologiji sindromov POTS in CRPS.
The CHMP noted the recommendations to the MAHs that had been made by the PRAC in terms of future monitoring.
Odbor CHMP se je seznanil s priporočili odbora PRAC imetnikom dovoljenj za promet z zdravilom v zvezi z nadaljnjim spremljanjem.
The PRAC therefore considered the results of a large published study which showed no link between HPV vaccine and CFS, as relevant for the current review.
Odbor PRAC je zato presodil, da so rezultati velike objavljene študije, ki ni pokazala povezave med cepivom proti virusu HPV in sindromom CFS, pomembni za trenutni pregled.
The PRAC confirmed that the benefit-risk balance of the HPV vaccines (Cervarix, Gardasil, Gardasil 9 and Silgard) remains favourable and recommends the maintenance of the marketing authorisations.
Odbor PRAC je potrdil, da razmerje med tveganji in koristmi cepiv proti virusu HPV (Cervarix, Gardasil, Gardasil 9 in Silgard) ostaja ugodno, in priporoča ohranitev dovoljenja za promet z zdravilom.
The Committee, having considered all the information available, concluded that the evidence does not support a causal association between HPV vaccination and CRPS and/or POTS.
Potem ko je odbor pregledal vse razpoložljive informacije, je zaključil, da ni dokazov v podporo vzročne povezave med cepivom proti virusu HPV in sindromom CRPS oziroma POTS.
These syndromes have been subject to previous repeated review by PRAC.
Odbor PRAC je ta dva sindroma obravnaval že pri predhodnih pregledih.
More than 80 million girls and women worldwide have now received these vaccines, and in some European countries they have been given to 90% of the age group recommended for vaccination.
V nekaterih evropskih državah je bilo cepljenih 90 % posameznic v starostni skupini, za katero se cepljenje
The CHMP, as a consequence, considers that the benefit-risk balance of HPV vaccines (Cervarix, Gardasil, Gardasil 9 and Silgard) remains favourable and therefore recommends the maintenance of the marketing authorisations.
Odbor PRAC je posledično presodil, da razmerje med tveganji in koristmi cepiv proti virusu HPV (Cervarix, Gardasil, Gardasil 9 in Silgard) ostaja ugodno, in zato priporoča ohranitev dovoljenja za promet z zdravilom.
Overall, the comparisons of observed versus expected number of spontaneous reports do not suggest an increased occurrence of CRPS in relation to the HPV vaccines.
Na splošno primerjave med dejanskim in pričakovanim številom spontanih poročil ne kažejo na povečano pojavnost sindroma CRPS v povezavi s cepivi proti virusu HPV.
The incidence of CRPS in the Gardasil/Silgard and Gardasil 9 clinical trials was less than 1 case per 10,000 person-years and comparable in the Gardasil/Silgard and Gardasil 9 and corresponding placebo cohorts.
Pojavnost sindroma CRPS v kliničnih preskušanjih s cepivom Gardasil/Silgard in Gardasil 9 je bila manj kot en primer na 10 000 oseb-let, pojavnost med kohortami, cepljenimi s cepivom Gardasil/Silgard, Gardasil 9 in ustreznim placebom, pa je bila primerljiva.
The incidence of POTS in the Gardasil/Silgard and Gardasil 9 clinical trials was less than 1 case per 10,000 person-years and comparable in the Gardasil/Silgard/Gardasil 9 and corresponding placebo cohorts.
Pojavnost sindroma POTS v kliničnih preskušanjih s cepivom Gardasil/Silgard in Gardasil 9 je bila manj kot en primer na 10 000 oseb-let, pojavnost med kohortami, cepljenimi s cepivom Gardasil/Silgard, Gardasil 9 in ustreznim placebom, pa je bila primerljiva.
Available estimates suggest that at least 150 girls and young women per million may develop POTS each year.
Razpoložljive ocene kažejo, da se sindrom POTS na leto lahko pojavi pri vsaj 150 deklicah in mladih ženskah na milijon.
The study found no association between HPV vaccine and any of the conditions studied.
V študiji niso našli povezave med cepivom proti virusu HPV in preučevanimi bolezenskimi stanji.
The results of a large published study2 showed no link between HPV vaccine and CFS.
Rezultati velike objavljene študije2 niso pokazali povezave med cepivom proti virusu HPV in sindromom CFS.
No cases were identified in the Cervarix and comparator cohorts.
V kohorti, cepljeni s cepivom Cervarix, in primerjalni kohorti ni bilo nobenega primera.
Available estimates suggest that in the general population around 150 girls and young women per million aged 10 to 19 years may develop CRPS each year.
Razpoložljive ocene kažejo, da se sindrom CRPS v splošnem prebivalstvu na leto pojavi pri približno 150 deklicah in mladih ženskah, starih od 10 do 19 let, na milijon.
Furthermore, the detailed review of the reports of CRPS did not show a consistent pattern regarding time-to-onset (TTO) following vaccination or clinical characteristics.
Poleg tega podroben pregled poročil o sindromu CRPS ni pokazal skladnega vzorca glede časa do pojava (ang.
general population around 150 girls and young women per million aged 10 to 19 years may develop CRPS each year, and at least 150 girls and young women per million may develop POTS each year.
Vendar pa razpoložljive ocene kažejo, da se sindrom CRPS v splošnem prebivalstvu na leto pojavi pri približno 150 deklicah in mladih ženskah, starih od 10 do 19 let, na milijon, sindrom POTS pa se na leto pojavi pri vsaj 150 deklicah in mladih ženskah na milijon.
Furthermore, the detailed review of the reports did not show a consistent pattern regarding time-toonset (TTO) following vaccination or clinical characteristics.
Poleg tega podroben pregled poročil ni pokazal skladnega vzorca glede časa do pojava (ang.
Overall, available data do not provide support for a causal relation between HPV vaccines and POTS.
Na sploh razpoložljivi podatki ne kažejo na vzročno povezavo med cepivi proti virusu HPV in sindromom POTS.
Overall, available data do not provide support for a causal association between HPV vaccines and CRPS.
Na sploh razpoložljivi podatki ne kažejo na vzročno povezavo med cepivi proti virusu HPV in sindromom CRPS.
Further information on Lenvima can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije o zdravilu Lenvima so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The medicine is available as capsules (4 mg and 10 mg).
Zdravilo je na voljo v obliki kapsul (4 mg in 10 mg).
What measures are being taken to ensure the safe and effective use of Lenvima?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Lenvima?